US kidney care speciailst Evergreen Nephrology announced on Tuesday the appointment of David Young to its board of directors.
Young has served in leadership roles such as CEO of GenesisCare, president & CEO of Physicians Endoscopy Inc and COO of Privia Health Inc. He has also worked in senior-level positions at Smile Brands Inc McKesson Specialty Health and US Oncology Inc.
Young will continue to serve on the boards of GenesisCare Cayman Holdings, GenesisCare UK Ltd and Biocartis Holdings Inc.
Adam Boehler, Evergreen Nephrology executive chairman, said: "Evergreen is at an exciting point in its growth, forming new partnerships with nephrologists nationwide, aligning with new payors, and pioneering cutting-edge research. David's extensive operational, financial and executive leadership in healthcare will be invaluable as we pursue our work of providing exceptional kidney care tailored to each patient's journey."
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Invenra and Orion partner to develop bispecific antibody cancer therapies
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor
Diatech Pharmacogenetics expands Merck collaboration for colorectal cancer testing